Anti-VEGF

Francesco Bandello, M. Battaglia Parodi, A. J. Augustin, P. Iacono, R. O. Schlingemann, U. Schmidt-Erfurth, F. D. Verbraak

Research output: Book/ReportBook

1 Citation (Scopus)

Abstract

The development of therapy with anti-angiogenics or vascular endothelial growth factor inhibitors (anti-VEGF) has marked the beginning of a new era in neovascularization and macular edema treatment. Its main goals are the inhibition of growth and development of new vessels along with the reduction of vascular permeability. The advantages over conventional laser photocoagulation are evident as laser treatment always leaves scars and causes a retinal sensitivity deterioration.Starting with an outline of treatment principles, this volume covers all aspects of anti-VEGF therapy for ophthalmological disorders. In particular, specific chapters are dedicated to age-related macular degeneration, degenerative myopia, angioid streaks, inflammatory diseases, hereditary dystrophies, retinal vein occlusion, diabetic retinopathy, ocular tumors, as well as anterior segment neovascularization.The book gives an update on the application of anti-VEGF in ocular diseases to general ophthalmologists as well as retina specialists.

Original languageEnglish
PublisherS. Karger AG
Number of pages144
ISBN (Print)9783805595308, 9783805595292
DOIs
Publication statusPublished - Aug 13 2010

Fingerprint

Vascular Endothelial Growth Factor A
Lasers
Angioid Streaks
Degenerative Myopia
Therapeutics
Retinal Vein Occlusion
Inborn Genetic Diseases
Macular Edema
Eye Diseases
Light Coagulation
Macular Degeneration
Capillary Permeability
Diabetic Retinopathy
Growth and Development
Cicatrix
Retina
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Bandello, F., Parodi, M. B., Augustin, A. J., Iacono, P., Schlingemann, R. O., Schmidt-Erfurth, U., & Verbraak, F. D. (2010). Anti-VEGF. S. Karger AG. https://doi.org/10.1159/isbn.978-3-8055-9530-8

Anti-VEGF. / Bandello, Francesco; Parodi, M. Battaglia; Augustin, A. J.; Iacono, P.; Schlingemann, R. O.; Schmidt-Erfurth, U.; Verbraak, F. D.

S. Karger AG, 2010. 144 p.

Research output: Book/ReportBook

Bandello, F, Parodi, MB, Augustin, AJ, Iacono, P, Schlingemann, RO, Schmidt-Erfurth, U & Verbraak, FD 2010, Anti-VEGF. S. Karger AG. https://doi.org/10.1159/isbn.978-3-8055-9530-8
Bandello F, Parodi MB, Augustin AJ, Iacono P, Schlingemann RO, Schmidt-Erfurth U et al. Anti-VEGF. S. Karger AG, 2010. 144 p. https://doi.org/10.1159/isbn.978-3-8055-9530-8
Bandello, Francesco ; Parodi, M. Battaglia ; Augustin, A. J. ; Iacono, P. ; Schlingemann, R. O. ; Schmidt-Erfurth, U. ; Verbraak, F. D. / Anti-VEGF. S. Karger AG, 2010. 144 p.
@book{5b6668265a3c4958a9f76b16888a38db,
title = "Anti-VEGF",
abstract = "The development of therapy with anti-angiogenics or vascular endothelial growth factor inhibitors (anti-VEGF) has marked the beginning of a new era in neovascularization and macular edema treatment. Its main goals are the inhibition of growth and development of new vessels along with the reduction of vascular permeability. The advantages over conventional laser photocoagulation are evident as laser treatment always leaves scars and causes a retinal sensitivity deterioration.Starting with an outline of treatment principles, this volume covers all aspects of anti-VEGF therapy for ophthalmological disorders. In particular, specific chapters are dedicated to age-related macular degeneration, degenerative myopia, angioid streaks, inflammatory diseases, hereditary dystrophies, retinal vein occlusion, diabetic retinopathy, ocular tumors, as well as anterior segment neovascularization.The book gives an update on the application of anti-VEGF in ocular diseases to general ophthalmologists as well as retina specialists.",
author = "Francesco Bandello and Parodi, {M. Battaglia} and Augustin, {A. J.} and P. Iacono and Schlingemann, {R. O.} and U. Schmidt-Erfurth and Verbraak, {F. D.}",
year = "2010",
month = "8",
day = "13",
doi = "10.1159/isbn.978-3-8055-9530-8",
language = "English",
isbn = "9783805595308",
publisher = "S. Karger AG",

}

TY - BOOK

T1 - Anti-VEGF

AU - Bandello, Francesco

AU - Parodi, M. Battaglia

AU - Augustin, A. J.

AU - Iacono, P.

AU - Schlingemann, R. O.

AU - Schmidt-Erfurth, U.

AU - Verbraak, F. D.

PY - 2010/8/13

Y1 - 2010/8/13

N2 - The development of therapy with anti-angiogenics or vascular endothelial growth factor inhibitors (anti-VEGF) has marked the beginning of a new era in neovascularization and macular edema treatment. Its main goals are the inhibition of growth and development of new vessels along with the reduction of vascular permeability. The advantages over conventional laser photocoagulation are evident as laser treatment always leaves scars and causes a retinal sensitivity deterioration.Starting with an outline of treatment principles, this volume covers all aspects of anti-VEGF therapy for ophthalmological disorders. In particular, specific chapters are dedicated to age-related macular degeneration, degenerative myopia, angioid streaks, inflammatory diseases, hereditary dystrophies, retinal vein occlusion, diabetic retinopathy, ocular tumors, as well as anterior segment neovascularization.The book gives an update on the application of anti-VEGF in ocular diseases to general ophthalmologists as well as retina specialists.

AB - The development of therapy with anti-angiogenics or vascular endothelial growth factor inhibitors (anti-VEGF) has marked the beginning of a new era in neovascularization and macular edema treatment. Its main goals are the inhibition of growth and development of new vessels along with the reduction of vascular permeability. The advantages over conventional laser photocoagulation are evident as laser treatment always leaves scars and causes a retinal sensitivity deterioration.Starting with an outline of treatment principles, this volume covers all aspects of anti-VEGF therapy for ophthalmological disorders. In particular, specific chapters are dedicated to age-related macular degeneration, degenerative myopia, angioid streaks, inflammatory diseases, hereditary dystrophies, retinal vein occlusion, diabetic retinopathy, ocular tumors, as well as anterior segment neovascularization.The book gives an update on the application of anti-VEGF in ocular diseases to general ophthalmologists as well as retina specialists.

UR - http://www.scopus.com/inward/record.url?scp=84925957027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925957027&partnerID=8YFLogxK

U2 - 10.1159/isbn.978-3-8055-9530-8

DO - 10.1159/isbn.978-3-8055-9530-8

M3 - Book

AN - SCOPUS:84925957027

SN - 9783805595308

SN - 9783805595292

BT - Anti-VEGF

PB - S. Karger AG

ER -